Additional Information

Description

MOUNJARO® (tirzepatide) is a once-weekly injectable prescription medication used to improve blood sugar control in adults with type 2 diabetes mellitus. It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which works by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying. The prefilled pen delivers a precise 12.5 mg/0.5 mL dose, offering convenience and ease of use for patients. MOUNJARO® should be stored refrigerated, but can be kept at room temperature for up to 21 days if needed.

Patients using MOUNJARO® should be monitored for potential side effects, including gastrointestinal symptoms (e.g., nausea, diarrhea) and more serious risks such as pancreatitis or thyroid tumors. It is contraindicated in individuals with a history of medullary thyroid carcinoma or MEN 2. Healthcare providers should review the full prescribing information and counsel patients on proper administration, storage, and signs of adverse reactions.

MOUNJARO® represents an innovative therapeutic option for managing type 2 diabetes, with clinical trials demonstrating significant improvements in glycemic control and potential weight loss benefits.

For complete prescribing information, refer to the DailyMed link or consult the official FDA-approved label.

This summary is for informational purposes only and does not replace professional medical advice. Always consult a healthcare provider before starting or changing treatment.